Anti-stroke biologics:from recombinant proteins to stem cells and organoids  

作　　者：Zhu-Wei Miao Zhi Wang Si-Li Zheng Shu-Na Wang Chao-Yu Miao 

机构地区：[1]Department of Pharmacology,Second Military Medical University/Naval Medical University,Shanghai,China

出　　处：《Stroke & Vascular Neurology》2024年第5期467-480,共14页卒中与血管神经病学（英文）

基　　金：National Natural Science Foundation of China(82030110 and 82330117 to C-YM,82104166 to ZW).

摘　　要：The use of biologics in various diseases has dramatically increased in recent years.Stroke,a cerebrovascular disease,is the second most common cause of death,and the leading cause of disability with high morbidity worldwide.For biologics applied in the treatment of acute ischaemic stroke,alteplase is the only thrombolytic agent.Meanwhile,current clinical trials show that two recombinant proteins,tenecteplase and non-immunogenic staphylokinase,are most promising as new thrombolytic agents for acute ischaemic stroke therapy.In addition,stem cell-based therapy,which uses stem cells or organoids for stroke treatment,has shown promising results in preclinical and early clinical studies.These strategies for acute ischaemic stroke mainly rely on the unique properties of undifferentiated cells to facilitate tissue repair and regeneration.However,there is a still considerable journey ahead before these approaches become routine clinical use.This includes optimising cell delivery methods,determining the ideal cell type and dosage,and addressing long-term safety concerns.This review introduces the current or promising recombinant proteins for thrombolysis therapy in ischaemic stroke and highlights the promise and challenges of stem cells and cerebral organoids in stroke therapy.

关 键 词：DOSAGE ROUTINE treatment 

分 类 号：R743.3[医药卫生—神经病学与精神病学]